Stock 300636 JIANGXI SYNERGY PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Jiangxi Synergy Pharmaceutical Co., Ltd.

Equities

300636

CNE100002P83

End-of-day quote Shenzhen S.E.
Other stock markets
 18:00:00 2024-06-25 EDT 		5-day change 1st Jan Change
10.32 CNY +3.30% Intraday chart for Jiangxi Synergy Pharmaceutical Co., Ltd. -3.28% -2.09%
06-24 Jiangxi Synergy Pharmaceutical Co., Ltd.(XSEC:300636) dropped from S&P Global BMI Index CI
05-20 Jiangxi Synergy Pharmaceutical Co., Ltd. Approves Board Appointments CI

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company returns high margins, thereby supporting business profitability.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • The firm trades with high earnings multiples: 24.57 times its 2024 earnings per share.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
JIANGXI SYNERGY PHARMACEUTICAL CO., LTD. Stock Jiangxi Synergy Pharmaceutical Co., Ltd.
-2.09% 575M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.31% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.25% 654B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.47% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.95% 337B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.67% 302B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 247B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+2.09% 229B
A+
NOVARTIS AG Stock Novartis AG
+13.03% 219B
B-
AMGEN INC. Stock Amgen Inc.
+9.53% 171B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 300636 Stock
  4. Ratings Jiangxi Synergy Pharmaceutical Co., Ltd.